U.S. markets closed

Eisai Co., Ltd. (ESALY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
96.19+0.95 (+1.00%)
At close: 3:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close95.24
Open98.06
Bid0.00 x 0
Ask0.00 x 0
Day's Range95.69 - 98.06
52 Week Range61.95 - 129.79
Volume62,777
Avg. Volume44,133
Market Cap28.026B
Beta (5Y Monthly)0.50
PE Ratio (TTM)71.62
EPS (TTM)1.34
Earnings DateN/A
Forward Dividend & Yield1.50 (1.56%)
Ex-Dividend DateMar 29, 2021
1y Target Est74.29
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Reuters

    Japan's Nikkei ends higher on economic rebound hopes; Eisai drags Topix

    Japan's Nikkei index closed higher on Thursday, as shipping firms rose on prospects of more economic reopenings and drugmakers were boosted by reports of government support. Signs that more economies are reopening amid a steady vaccine rollout underpinned shipping firms, with Nippon Yusen jumping 3.65% to be the biggest gainer on the Nikkei. Japan plans to finish vaccinating all citizens who have applied for shots by October-November, Prime Minister Yoshihide Suga said during a debate between party leaders on Wednesday.

  • Reuters

    Japanese shares rise, Eisai drops after 2 days of limit-up gains

    Japanese shares inched higher on Thursday, as the service sector gained on prospects of economic reopenings and drugmakers rose on reports of government support, though Eisai eased after a big jump following U.S. approval of its Alzheimer's disease drug. Hopes of economic reopenings amid a steady vaccine rollout underpinned real-estate companies, railway operators and airline companies, though some of them started to lose momentum after a steady rally so far this month. Japan plans to finish vaccinating all citizens who have applied for shots by October-November, Prime Minister Yoshihide Suga said during a debate between party leaders on Wednesday.

  • TheStreet.com

    Biogen's Japanese Partner on Alzheimer's Drug Set for Gains

    Eisai is working on another promising drug candidate to combat Alzheimer's disease, and will benefit from a split of the profits for Aduhelm.